CTSO Earnings

CTSO reported its FY2025Q3 earnings on 2025-11-13, showcasing a revenue of 9.00M against an estimate of 10.00M, resulting in a -5.33% surprise. The EPS was -0.04, surpassing the expected -0.05 by 20% . The stock experienced a -0.83% price change on the earnings day and a -4.01% change over the next five days, reflecting market reactions to the results.

Following CTSO's FY2025Q3 earnings announcement on 2025-11-13, the stock price moved by -0.83% on the day of the release. Over the subsequent five days, it saw a -4.01% change. Historically, CTSO's stock price tends to shift by an average of +16.94% in the 10 days leading up to earnings and +6.67% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate CTSO’s annual revenue to reach 10.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -0.83% and EPS estimates Revise Downward by -0.32% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between CTSO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -0.83%, while EPS estimates moved Revise Downward by -0.32% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CTSO's stock price typically moves by +16.94% in the 10 days before its earnings and +6.67% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 10.00M.

The earnings call presents a mixed picture. Financial performance shows positive growth in revenue and gross margin, but challenges like FDA delays, cash flow issues, and market competition create uncertainties. The Q&A session revealed management's optimism about margin improvement and sepsis treatment expansion but lacked clarity on German sales restructuring. Given these factors, the stock is likely to experience a neutral movement in the short term, as positive financial indicators are offset by regulatory and operational challenges.